CHICAGO — Since its approval in 2020, Tepezza has become a go-to treatment for moderate to severe thyroid eye disease, unseating orbital decompression as the most used treatment, according to a presenter here.
“Our study demonstrates a notable change in practice pattern for the treatment of moderate to severe thyroid eye disease at one academic institution since teprotumumab became widely available,” Nicole J. Topilow, MD, of the University of California San Diego, said at the ASOPRS Fall Scientific Symposium.
Topilow presented a retrospective chart review that included 41